Disclosed is a roller compacted solid oral dosage form comprising a therapeutically effective amount of Aliskiren or a pharmaceutically acceptable salt thereof, wherein active ingredient is present in an amount of more than 38% by weight based on the total weight of the oral dosage form and wherein the dosage form further comprises calcium hydrogen phosphate as a filler. Also disclosed is the use of the solid oral dosage form for the manufacture of a medicament for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache or chronic heart failure.
